Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study
These final OS data show the sustained long-term systemic and intracranial efficacy of alectinib in the first-line treatment of ALK-positive NSCLC and confirm alectinib as a standard of care in this setting.
Authors
- Isabelle Rooney
- J.S. Ahn
- Astrid Scalori
- Shirish M. Gadgeel (ORCID: https://orcid.org/0000-0001-5240-3811)
- Volkmar Henschel
- M. Pérol
- Rafael Rosell (ORCID: https://orcid.org/0000-0003-0817-3400)
- V. McNally
- Rafał Dziadziuszko (ORCID: https://orcid.org/0000-0001-8080-9843)
- Parneet Kaur Cheema (ORCID: https://orcid.org/0000-0002-9680-7073)
- Vlatka Smoljanović
- Solange Peters (ORCID: https://orcid.org/0000-0002-0412-7143)
- T. Mok
- D. Ross Camidge (ORCID: https://orcid.org/0000-0003-3430-3213)
- A. Shaw (ORCID: https://orcid.org/0000-0002-1004-2226)
- W. Marston Linehan (ORCID: https://orcid.org/0000-0001-7373-3916)
- Nick Pavlakis (ORCID: https://orcid.org/0000-0002-1738-0316)
- Li Zhang (ORCID: https://orcid.org/0000-0003-0595-0761)
- Dong‐Wan Kim (ORCID: https://orcid.org/0000-0001-5124-7132)
- Dong-Jun Lim (ORCID: https://orcid.org/0000-0002-2396-692X)
- A.A. Higgerson
Institutions
- Roche (Switzerland) (CH)
- The University of Sydney (AU)
- Sun Yat-sen University (CN)
- Chinese University of Hong Kong (HK)
- Royal North Shore Hospital (AU)
- Samsung Medical Center (KR)
- Centre Hospitalier Universitaire Vaudois (CH)
- Seoul National University Hospital (KR)
- Massachusetts General Hospital (US)
- The Barbara Ann Karmanos Cancer Institute (US)
- Instituto Oncológico Dr. Rosell (ES)
- Roche (United Kingdom) (GB)
- Dana-Farber Cancer Institute (US)
- Centre de Recherche en Cancérologie de Lyon (FR)
- William Osler Health System (CA)
- University of Colorado Cancer Center (US)
- National Cancer Centre Singapore (SG)
- Sun Yat-sen University Cancer Center (CN)
- Gdańsk Medical University (PL)
- University of Colorado Denver (US)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1016/j.annonc.2025.09.018
- Citations
- 6
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 9.11
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- F. Hoffmann-La Roche
- Regeneron Pharmaceuticals
- Novocure
- BeiGene
- Incyte
- Ipsen
- Genentech
- Foundation Medicine
- Daiichi Sankyo Europe